CLINICAL TRIAL OF GENE THERAPY FOR ARTHRITIS

Project: Research project

Project Details

Description

DESCRIPTION: (Adapted from investigator's abstract) This application
requests funding to help defray the costs of conducting the first human
trial in which a potentially therapeutic agent will be transferred to a
joint. The protocol was approved by the Recombinant DNA Advisory Committee
(RAC) of the NIH in June, 1994; a pre-IND meeting with the FDA was held in
10/94 and the IND itself is in the process of being filed. The applicants
propose to use a replication-defective retrovirus (MFG) carrying a cDNA
encoding the human interleukin-1 receptor antagonist protein (IRAP) to
transduce autologous human synovial cells grown ex vivo, and then to
reinject the cells into metacarpaphalageal joints (MCP) in 6 post-menopausal
patients with chronic rheumatoid arthritis rheumatoid arthritis (RA). The
Specific Aims are to: 1) establish synovial cell cultures from biopsies
from MCP joints from 6 patients with RA and transduce the cells with a
replication-defective retrovirus (MFG) carrying a cDNA encoding the human
IRAP; 2) transfer the autologous transduced synoviocytes to MCP joints of
patients 1 week before MCP arthroplasty; and 3) after 1 week, at the time of
joint replacement surgery, lavages will be performed and periarticular
tissues recovered to determine whether the IRAP gene has been successfully
transferred to the synovium and expressed intrarticularly, and whether a
local biological response to the transgene product has occurred based on
evaluation of the expression pattern of cytokines and inflammatory markers,
and whether there has been changes in articular cartilage glycosaminoglycan
(GAG) synthesis. The IRAP was selected because it is a naturally occurring
antagonist of IL-1alpha and IL-1beta, cytokines that play a role in a
variety of immune and inflammatory diosorders. IRAP competes for binding to
the IL-1 receptor but fails to transduce biological responses. The
applicants suggest that the proposed human studies should advance the
development of gene treatments for arthritis and other diseases of bones and
joints.
StatusNot started

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.